CLASS II Drug recall · Reported 25 Aug 2021 · FDA Enforcement Report

Octreotide Acetate Injection 100 mcg/mL single-dose vial recalled

Teva Pharmaceuticals U is recalling Octreotide Acetate Injection 100 mcg/mL single-dose vial, distributed nationwide in the US. The recall was initiated on 29 Jul 2021 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: 31327466B, exp. date 08/2021
Quantity recalled3,067 vials

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0744-2021
FDA event ID
88442
Recalling firm
Teva Pharmaceuticals U, Parsippany, NJ
Classification
Class II
Status
Terminated
Recall initiated
29 Jul 2021
FDA classified
16 Aug 2021
Reported
25 Aug 2021
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Sterility

Timeline

29 Jul 2021Recall initiated by company
16 Aug 2021Classified by FDA+18 days
25 Aug 2021Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Lack of Assurance of Sterility

A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.

Product as listed by the FDA

Octreotide Acetate Injection 100 mcg/mL, 1 mL single-dose vial, Rx only, Teva Pharmaceuticals USA. Inc. North Wales, PA 19454, NDC 0703-3311-01

Where it was distributed

Product was distributed Nationwide, including Puerto Rico.

Nationwide Puerto Rico

Questions about this recall

Is Octreotide Acetate Injection 100 mcg/mL single-dose vial recalled?

Yes. Teva Pharmaceuticals U recalled Octreotide Acetate Injection 100 mcg/mL single-dose vial on 29 Jul 2021. The recall is Class II and its status is Terminated. Recall number D-0744-2021.

Why was it recalled?

Lack of Assurance of Sterility

Which lots are affected?

Lot #: 31327466B, exp. date 08/2021

Where was it sold?

Product was distributed Nationwide, including Puerto Rico.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Teva Pharmaceuticals U

All 196

Other Octreotide recalls

All 11
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIOctreotide Acetate for Injectable Suspension recalledOctreotide AcetateTeva Pharmaceuticals USASterilityNationwide
DrugCLASS IIOctreotide Acetate for Injectable Suspension recalledOctreotide AcetateTeva Pharmaceuticals USASterilityNationwide
DrugCLASS IIOctreotide Acetate for Injectable Suspension recalledOctreotide AcetateTeva Pharmaceuticals USASterilityNationwide
DrugCLASS IIOctreotide Acetate for Injectable Suspension recalledOctreotide AcetateTeva Pharmaceuticals USASterilityNationwide
DrugCLASS IOctreotide Acetate Injection 500 mcg/mL recalled by ViatrisOctreotide AcetateViatrisParticulate MatterNationwide